

AUG 3 2000

K002212



Micro Therapeutics, Inc.

## 510(k) Summary of Safety and Effectiveness

Prepared July 20, 2000

TRADE NAME	Micro Therapeutics, Inc. Mirage™ Hydrophilic Guidewire (.008" outer diameter, 200 cm length)		
GENERIC NAME	Hydrophilic Guidewire	CLASSIFICATION	Class II (21 CFR 870.1330)
SUBMITTED BY	Micro Therapeutics, Inc. 2 Goodyear Irvine, CA 92618	CONTACT	Maribelle Aguinaldo Regulatory Affairs (949) 837-3700
PREDICATE DEVICE	SilverSpeed™ Hydrophilic Guidewire - K982543, K993297, K001454 (.010, .014, .018" outer diameters; 145, 165, 175, or 200 cm lengths)		
DEVICE DESCRIPTION	The Mirage™ Hydrophilic Guidewire is a stainless steel guidewire with a radiopaque, platinum distal coil. The guidewire is hydrophilically coated from the shapeable platinum coil up to the proximal 30 cm of the guidewire. Included within the sterile pouch is a torque device to assist in guidewire manipulation and a guidewire introducer to ease the introduction of the guidewire into the catheter hub and/or hemostasis valve.		
INDICATIONS FOR USE	The Mirage™ Hydrophilic Guidewire is indicated for general intravascular use to aid in the selective placement of catheters in the peripheral, visceral and cerebral vasculature during diagnostic and/or therapeutic procedures.		
SAFETY AND PERFORMANCE TESTS	<p>The Mirage™ and the SilverSpeed™ hydrophilic guidewires are manufacturing using the same materials. Biocompatibility of the SilverSpeed™ guidewire was verified in accordance with ISO 10993-1, <i>Biological Evaluation of Medical Devices</i>. Test results confirmed biocompatibility of the SilverSpeed™ guidewire when tested as an external communicating, blood contact, short duration (&lt;24 hrs.) device.</p> <p>The <i>in vitro</i> performance tests conducted were based on the changes implemented in the Mirage™ hydrophilic guidewire and included dimensional/visual, torque strength, coating push/pull force, coating adherence, tip flexibility, tip buckling, and simulated bench testing using a dynamic vascular/neuro vascular model. Tests were conducted on non-aged (zero time) samples and samples subjected to accelerated aging. All tests yielded acceptable results substantially equivalent to the predicate device.</p>		
SUMMARY OF SUBSTANTIAL EQUIVALENCE	The Mirage™ Hydrophilic Guidewire is substantially equivalent to the predicate device in intended use and principles of operation.		



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

AUG 3 2000

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Maribelle Aguinaldo  
Regulatory Affairs  
Micro Therapeutics, Inc.  
2 Goodyear  
Irvine, CA 92618

Re: K002212  
Trade Name: Mirage™ Hydrophilic Guidewire  
Regulatory Class: II (two)  
Product Code: 74 DQX  
Dated: July 20, 2000  
Received: July 21, 2000

Dear Ms. Aguinaldo:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Ms. Maribelle Aguinaldo


This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4586. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



James E. Dillard III  
Director  
Division of Cardiovascular and  
Respiratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health



Enclosure

510(k) Number: K002212

Device Name: Mirage™ Hydrophilic Guidewire


Indications for Use: Indicated for general intravascular use to aid in the selective placement of catheters in the peripheral, visceral and cerebral vasculature during diagnostic and/or therapeutic procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over the Counter Use \_\_\_\_\_

(Per 21 CFR 801.109)



\_\_\_\_\_  
(Division Sign-Off)  
Division of Cardiovascular, Respiratory,  
and Neurological Devices